International Journal of Healthcare Sciences ISSN 2348-5728 (Online)
Vol. 4, Issue 2, pp: (1999-2006), Month: October 2016 - March 2017, Available at: www.researchpublish.com

Dermatological Lesions of Pemphigus Vulgaris, And Treatment Approaches

[1] Yasser Yahya Ali Al-Habtar Asiri, [2]Abdullah Khallufah Abdullah Asiri,
[3]Ibrahim Hassan A. Abu Saq, [4]Naif Dahman Abdullah Alshehri,
[5]Salem Mohammed Alqarni, [6]Yasser Dhafer Ali Alshahrani,
[7]Abdulwahab Salem Ahmad Alghamdi, [8]Abdullah Ali Abdullah Alqahtani,
[9]Hassan Fayez Abdullah Alshehri, [10]Saleh Abdullah M Alqahtani,
[11]Yazeed Mohammed Yahya Al Hadi, [12]Fahad Abdulrahman Alazragi

Abstract: **The aim of this review study was to discuss the treatment approaches of Pemphigus vulgaris (PV), and also to review the dermatological lesions which are mostly oral mucosal and face area lesions. We conducted a computerized search through; PubMed, Embase, and the Cochrane Central Register of Controlled Trials databases, for relevant articles reporting data on lesions and treatment of pemphigus vulgaris up to December, 2016. And reference lists were searched for more relevant articles concerned with treatment modality for pemphigus vulgaris. Restriction were applied in the search method to English language and only human subjects. Pemphigus vulgaris is a chronic autoimmune mucocutaneous disease that at first materializes through intraoral lesions, which infected various other mucous membranes and the skin. The etiology of pemphigus vulgaris is still unknown, although the disease has brought in substantial rate of interest. The pemphigus group of disease is characterized by the production of autoantibodies versus intercellular materials and is thus identified as autoimmune diseases. In pemphigus vulgaris, treatment with systemic glucocorticosteroids is lifesaving; it could, nevertheless, create severe side effects, consisting of death. A patient with pemphigus vulgaris as well as myasthenia gravis was treated for roughly 5 years with the cholinomimetic Mestinon (pyridostigmine bromide), Imuran (azathioprine), and a topical corticosteroid gel before they have to present systemic glucocorticosteroids.**

Keywords: **Pemphigus vulgaris (PV), Cochrane Central Register of Controlled Trials.**

1. INTRODUCTION

Pemphigus vulgaris (PV) is the most frequently observed member of a group of chronic autoimmune mucocutaneous diseases defined by the development of intraepithelial sores. It is an uncommon disease (0.1-0.5 cases/100,000 inhabitants/yr), with onset in the fifth or 6th decade of life [(1,2,3)]. PV is irregular in teens and children but some situations have been reported, for that reason it needs to be thought about in the differential diagnosis at these ages [(4,5)].

As in other diseases, there is a greater occurrence of PV at below greater latitudes [(6)]. It has additionally been observed a lot more regularly in particular peoples, e.g., Ashkenazi Jews, Mediterranean populaces and also Asians (especially Indians and also Japanese) [(4,5,6),] who show some hereditary proneness. PV is considered an idiopathic disease, a collection of environmental factors that cause the disease have been identified, consisting of medications (particularly thiol-containing medications, e.g., penicillamine and also angiotensin-converting enzyme inhibitors), diet plan (garlic), and viral or physical representatives [(7,8)]. Although these are seldom reasons, they ought to be investigated in patients with a recent medical diagnosis of PV [(9)]. No partnership has actually been reported with previous direct exposure to the antigen, which is discovered in mucosal pemphigoid and also a few other diseases. Many research studies have actually shown the contribution of hereditary factors to the advancement of this disease, with records of its partnership with MHC

genes, and study is recurring right into other prospect genes [10]. There have also been records on the frequency of PV in specific populations and also on situations of pemphigus familiaris [10].

Medically, the oral sores are characterized by blisters that quickly rupture, causing excruciating disintegrations. While any kind of location in the mouth can be included, the soft taste buds, buccal mucosa, as well as lips are primarily impacted [11,12]. The diagnosis depends on biopsy confirmation of intraepithelial blister formation, acantholysis, as well as the visibility of Tzanck cells [11]. This short article talks about the instance record of pemphigus vulgaris with unknown etiology together with overview of disease (**Figures 1**).

With appropriate treatment, the mortality price of PV has been considerably minimized, but still stands at an inappropriate rate of approximately 5-6%, with most fatalities being the outcome of negative effects of immunosuppressive agents rather than the result of the disease itself or disease sequelae [2,4]. The only recognized factor that dramatically minimizes survival rates is a later age of beginning of PV [5]. A poorer prognosis for attaining total remission is seen when the disease is much more extensive, extra extreme at beginning, or when it responds gradually to therapy [4]. In general, a patient with lesions centered to the mucosa has a far better prognosis compared to a patient with mucocutaneous lesions [6].

The aim of this review study was to discuss the treatment approaches of Pemphigus vulgaris (PV), and also to review the dermatological lesions which are mostly oral mucosal and face area lesions.



Figure1: Right buccal mucosa showing ulceration

2. METHODOLOGY

We conducted a computerized search through; PubMed, Embase, and the Cochrane Central Register of Controlled Trials databases, for relevant articles reporting data on lesions and treatment of pemphigus vulgaris up to December, 2016. And reference lists were searched for more relevant articles concerned with treatment modality for pemphigus vulgaris. Restriction were applied in the search method to English language and only human subjects.

3. RESULTS

- **Oral Clinical Presentation of Pemphigus vulgaris (PV):**

Oral lesions are the very first symptom of the disease in 50-90% of cases [13,14,15]. Nonetheless, they are the first indication in only 18% of outpatients at dermatology centers [15]. In patients with very early beginning of oral lesions, these continue to be the sole symptoms of the disease for a duration of 2-6 months till the appearance of cutaneous sores, making up the relevance of oral manifestations for skin specialists [13,15,17,23]. Some researchers have actually found major distinctions in the occurrence of oral lesions as very first indication of PV among unique geographic areas, e.g., 66% in Bulgaria, 83% in Italia, and also 92% in Israel [15]. Oral sores have a very slim roof covering and also conveniently tear as a result of oral traumas, triggering numerous chronic unpleasant bleeding abscess and disintegrations that recover with trouble [17,19].

Patients report pain in the mouth and also a burning experience, particularly when taking in spicy or acidic food [17,21]. Blisters could appear at any localization of the oral mucosa, although the most regular sites are those based on friction, such as the soft palate, buccal mucosa (**Figure 1**), forward tongue (Figure 2), gingiva, and also lower lip (**Figure 2**) [13,20].

Persistent and also several erosions appear on the oral mucosa during onset of PV. Infrequently, they are localized on the gingiva (Figure 4), particularly the cost-free gingiva, where they are difficult to identify as sore lesions. In advanced stages of PV, erosive or desquamative gingivitis can be observed [13,19]. Various other oral indications include sialorrhea, halitosis, and also the constant formation of brownish or blackish crusts at the vermillion border (13).

PV can entail other mucosae besides the oral mucosa, consisting of conjunctive, nasal, pharyngeal, laryngeal, esophageal, genital, and anal mucosae [14,20]. Sores subsequently or often simultaneously appear on the skin, although they could be asymptomatic as well as are not usually pruritic. Blisters are more likely to be discovered undamaged on the skin than on mucosae (due to trauma) [13,14].

Virtually all (99%) associated cutaneous sores are diagnosed within 6 months compared with just 57% of oral lesions. Detection of oral lesions at the beginning of the disease would allow an earlier diagnosis and therapy, boosting the prognosis of patients [21]. PV is often chronic, with a modern rise in seriousness; it is deadly if not dealt with, because of dehydration, protein loss, and opportunistic infections [13,15].



Figure 3: Erosions on lower lip after disappearance of blister roofs.

- **Diagnosis of Pemphigus vulgaris (PV):**

The medical diagnosis of PV is based on 3 independent set of criteria: clinical attributes, histology, and also immunological examinations [17]. Visibility of this disease should be suspected in cases of persistent gingivostomatitis; consistent several oral disintegrations, or extreme desquamative or abrasive gingivitis [13,19]. One analysis technique has been to push with the finger on the skin to test for the look of a new sore (Nikolsky's indication). Although inquiries have been increased concerning its sensitivity and also uniqueness [13,19], it seems a very details method in the oral setup (96.3%) as well as might be really valuable in the initial diagnosis of oral blistering diseases [19].

Research laboratory exams include: Tzanck smear to spot acantholytic cells, beneficial in sores of the oral mucosa; basic histology of fresh blister specimens to find suprabasal acantholysis; straight immunofluorescence to identify intercellular down payments of immunoglobulin G, C3, m as well as protein on skin as well as perilesional skin, using 100% level of sensitivity; indirect immunofluorescence to find pemphigus antibodies in product; ELISA test making use of recombinant Dsg1 and also Dsg3 to gauge anti-Dsg1 as well as anti-Dsg3 antibodies in product; and also, when the medical diagnosis remains unpredictable, immunoprecipitation and immunoblotting strategies [13,14,19].

- **Differential Diagnosis of Oral Lesions:**

The differential medical diagnosis consists of various other skin-related diseases with feasible symptoms on the oral mucosa, including dermatitis herpetiformis, mucosal pemphigus, erythematous pemphigus, pemphigus foliaceus, or

benign chronic pemphigus familiaris [14]. The list below problems need to likewise be thought about: disseminated erythematous lupus, enteropathic acrodermatitis, Crohn's disease, hemorrhagic rectal colitis; and shortages in folic acid, vitamin B12, or hypochromic iron [21].

All of these differential medical diagnoses are summarized in (**Table 1**).

Table 1: Differential diagnosis of oral lesions in pemphigus vulgaris

Disease or condition	Clinical characteristics
Recurrent aphthous stomatitis	Appearance of ulcers (aphthae) in oral mucosa with yellowish base, surrounded by an erythematous halo and regular margins and that disappear without treatment. Acute course
Behçet's disease	Appearance of aphthae in the oral mucosa with genital and ocular ulcers
Eerythema multiforme	Target-shaped skin lesions, oral erosions, involvement of lips in the form of erosions and crusts
Erosive lichen planus	Appearance of Wickham striae and erosive lesions
Oral candidiasis	Whitish lesions that detach on scraping and atrophic erythematous areas
Acute herpetic gingivostomatitis	Prodromic symptoms followed by the onset of small yellowish vesicles that rapidly rupture, giving rise to ulcers with an erythematous halo. It affects free and attached g ingiva.
Impetigo	Bacterial infection with appearance of skin ulcers covered by a honey-colored crust. It affects face, arms and legs. It is more frequent in children.
Disease by linear IgA deposit	Symmetric blisters and pruritic lesions, target-shaped lesions
Mucosal pemphigoid or cicatricial pemphigoid	Possible manifestation of an underlying malignant disease: oral lesions do not precede skin lesions, and blisters are smaller with a shorter duration than in PV. They heal rapidly without scarring
Bullous pemphigus	Vesicles or tension blisters with clear content that develop on normal or erythematous skin; intense pruritus, symmetric lesions that appear on flexion areas, root of extremities, thighs, and abdomen; rare on mucosae.
Herpetiform dermatitis	1-3 cm erythemas that infiltrate palate and buccal mucosa; aphthae on labial mucosa. They appear months or years after the appearance of lesions on skin
Epidermolysis bullosa	Development of blisters with minimal pressure, ring-shaped atrophic scars on the inner surface of limbs and articulations
Paraneoplastic pemphigus	Autoimmune syndrome associated with lymphoproliferative neoplasm of B cells
Erythematous pemphigus	There are usually no oral lesions
Pemphigus foliaceus	There are usually no oral lesions
Chronic benign pemphigus familiaris	There are usually no oral lesions
Disseminated lupus erythematosus	Systemic signs (fever, asthenia) normally accompanied by petechiae, edemas and dry mouth
Crohn's disease and hemorrhagic rectal colitis	Mucocutaneous signs accompanied by abdominal pain, aphthae in oral mucosa, asthenia, weight loss, and anorexia
Folic acid or vitamin B12 deficiency	Oral pain, erythematous tongue, asthenia and anemia, paresthesias in limbs, and physical problems
Hypochromic iron deficiency	Pallor, fatigue, cephalalgias, vertigo, buzzing in the ears, irritability, insomnia, concentration problems, sensitivity to cold, anorexia and nausea
Enteropathic acrodermatitis	Loss of taste and smell, sight problems, intense diarrhea, alopecia, and hypertension

Treatment of Oral Lesions:

Oral sores are challenging, considering that their response to therapy is much slower in contrast to cutaneous sores [22]. Sores of the oral mucosa in patients with reduced titers of flowing antibodies might be managed (at least momentarily) with mouthwashes or topical creams that contain corticosteroids, e.g., 0.1% triamcinolone acetonide in orabase, 0.05%

fluocinolone acetonide, 0.05% clobetasol propionate, or 0.05% halobetasol. Intralesional injection of triamcinolone acetonide (20 µg/ L) or paramethasone every 7-15 days can be utilized in refractory lesions, however the treatment has to be taken out if symptoms do not improve after three shots [14,16,19,21,22].

As an enhance to therapy with systemic or neighborhood corticosteroids, the complying with procedures can be taken to enhance the health and wellbeing of patients: administering analgesics, preserving rigorous oral health making use of watered down disinfectant (chlorhexidine) mouthwashes, gum treatment, complying with a soft diet regimen without toxic irritants, examining prosthetic reconstructions, and using anti-candida therapy in patients on long-lasting corticosteroid therapies [15,21].

Factors that could intensify the disease include sunlight exposure, radiographs, anxiety, as well as traumas [22]. Because oral injuries can set off or aggravate PV, Bystryn et al. suggest the prophylactic management of 20 mg prednisone/day in addition to the patient's regular need for 5-7 days prior to any kind of oral treatment that is related to injury to the periodontals [22].

In PV patients with considerable oral lesions or skin involvement, the common treatment includes the combined management of corticosteroids and systemic immunosuppressant's to pay symptoms. After achieving this goal, an upkeep routine is started, utilizing the minimal possible dose able to manage the disease in order to lessen the negative effects of these medications [13,14,19,23]. There is no consensus on the optimum dose of corticosteroids to be made use of or on one of the most reliable immunosuppressant [24].

Research study developments have increased the therapeutic arsenal against PV, which now includes therapies with: pulse therapy (intravenous infusion of really high dosages of immunosuppressants momentarily duration); high dosages of intravenous immunoglobulin; plasmapheresis; immunospecific immunoadsorption; extracorporeal photopheresis with exposure of lotion to psoralens and UVA; antagonists of tumor necrosis factor a (TNFa); cholinergic villains; as well as anti- CD20 monoclonal antibodies (e.g., rituximab) [13,21]. Nonetheless, no treatment has shown supremacy over the others [23]. Actually, there is an absence of well-designed studies on the efficacy of the various brand-new PV treatments and also a scarcity of evidence-based professional guidelines. This can mainly be attributed to the low frequency of the disease as well as a failing to develop an agreement on terms utilized to evaluate the extent as well as define, activity, intensity, or healingremission of PV or promptly factors for evaluating the healing action [23,24]. In an attempt to resolve this concern, the American Academy of Dermatology (AAD) published an agreement affirmation in 2008 on follow-up periods and on the meaning of treatment failing/ success and recurrences [25].

Anti-tumor necrosis factor (TNF) agents:

TNF- has been suggested to be one of the cytokines in charge of causing acantholysis [26]. Case reports have recommended that both infliximab and etanercept, 2 anti-TNF representatives, could be effective therapy choices in PV [26,27,28]. To better check out the performance of anti-TNF representatives in PV, a randomized placebo-controlled trial of infliximab in subjects with PV obtaining prednisone was accomplished from 2006 until 2011 [29]. Individuals in the speculative team were randomized to get intravenous mixtures of infliximab (5mg/kg) at weeks 0, 2, 6 and also 14. Patients in the control team obtained the exact same dosing of sugar pill intravenous infusions. This research study was limited due to little example dimensions (there were only 10 participants in each group) as well as trouble in obtaining data from patients for each and every result procedure. One result measure that did reveal a potentially valuable use of anti-TNF representatives was the "Total prednisone dose required for participants to accomplish cessation of brand-new sores". The prednisone dose called for in the experimental group was 4009 mg while that in the placebo team was 6446 mg [30]. This study also made use of the Pemphigus Vulgaris Disease Activity (PVDA) score to quality participants' disease activity, with ratings varying from 0 to 3 (from none to extreme disease activity). (**Figure3**) No difference was discovered between the two teams for this outcome step, as neither group had any kind of patients with new sore scores of 3 for a one-month duration or old lesion scores of 3 in 2 consecutive months [30]. An additional recent case series of two patients with refractory PV showed that the addition of infliximab supplied no additional benefit. One of these patients, who had severe, persistent PV after several therapy failures, was begun on infliximab (5mg/kg at weeks 0, 2 as well as 6, and then every 2 months) in addition to prednisone (20 mg/day) and also dapsone (50 mg/day). Steroids were tapered after 4 lesions however infusions reappeared 2 weeks later and after a total amount of 8 mixtures infliximab was ceased as a result of absence of perceived benefit. In the second patient, when infliximab was offered along with a prednisone dosage of 20 mg/day, the patient did not create new lesions as well as previous sores began to recover. Nevertheless, at any time the dose of prednisone was lowered listed below 10 mg/day, the patient experienced a severe flare of her

mucocutaneous lesions and also infliximab was terminated after 7 mixtures due to lack of action [31]. While this research cannot support the efficiency of infliximab in the therapy of PV, the evidence might be restricted by the severity of the patients' disease. Both patients had stopped working therapy with several techniques of therapy, including corticosteroids with adjuvant immunosuppressants such as dapsone or mycophenolate mofetil, intravenous immunoglobulin as well as rituximab. The limited and also questionable understanding relating to the advantage of infliximab in PV enhances the requirement for larger studies to assess the efficiency of anti-TNF representatives as adjuvant therapy for PV.



Figure 3: Pemphigus vulgaris pathogenesis and emerging immune targeted treatment options.

Systemic corticosteroids:

While corticosteroids have actually been the mainstay of therapy of PV for over 50 years, their specific usage has actually been going through significant modifications in the past number of years. While there have actually been research studies reviewing the marginal doses of systemic steroids should control disease task, the optimum dosage and also regimen of systemic corticosteroids remain vague. One randomized controlled test reported that high-dose oral prednisolone (120-150 mg/d) is not significantly superior to low-dose oral prednisolone (45-60 mg/d) in lowering regression rates and boosting duration of remission [31]. A reliable preliminary dosage of corticosteroids has been suggested to be 1 mg/kg/d [32]. Others advise an initial oral prednisolone dosage of 40-60 mg/d and with extreme PV, 60-100 mg/d [33]. A randomized control test of 20 patients showed that pulsed oral dexamethasone (300 mg/d for 3 days) along with oral prednisolone and also azathioprine does not improve time to remission, period of remission or mortality. The pulsed steroid team experienced raised damaging occasions, with weight gain being the most frequently reported side effect [34]. Three of the patients receiving pulsed dexamethasone stopped the research study because of damaging effects including infection, high blood sugar degrees, myalgia and also cognitive disorder. The team that conducted this research study ended that conventional therapy, including prednisolone, 80 mg/day on a tapering schedule to 0 mg in 19 weeks and also azathioprine salt, 3 mg/kg continued for a year after tapering, is the most reliable regimen for patients with new disease task [34]. While systemic corticosteroids still continue to be the essential of treatment for PV, there is no consistency pertaining to advised doses.

4. CONCLUSION

Pemphigus vulgaris is a chronic autoimmune mucocutaneous disease that at first materializes through intraoral lesions, which infected various other mucous membranes and the skin. The etiology of pemphigus vulgaris is still unknown, although the disease has brought in substantial rate of interest. The pemphigus group of disease is characterized by the production of autoantibodies versus intercellular materials and is thus identified as autoimmune diseases. In pemphigus vulgaris, treatment with systemic glucocorticosteroids is lifesaving; it could, nevertheless, create severe side effects, consisting of death. A patient with pemphigus vulgaris as well as myasthenia gravis was treated for roughly 5 years with the cholinomimetic Mestinon (pyridostigmine bromide), Imuran (azathioprine), and a topical corticosteroid gel before the have to present systemic glucocorticosteroids.

REFERENCES

[1] Bystryn JC. Adjuvant therapy of pemphigus. Arch Dermatol 1984; 120: 941-51.

[2] Buchman AL. Side effects of corticosteroid therapy. J Clin Gastroenterol 2001; 33: 289-94.

[3] Bystryn JC, Steinman N. The adjuvant therapy of pemphigus- an update. Arch Dermatol 1996; 132: 203-12.

[4] Herbst A, Bystryn J. Patterns of remission in pemphigus vulgaris. J Am Acad Dermatol 2000; 42: 422-7.

[5] Shamsadini S, Fekri A, Farajzadeh S, et al. Determination of survival and hazard functions for pemphigus patients in Kerman, a southern province of Iran. Int J Dermatol 2006; 45: 688-771.

[6] Mourellou O, Chaidemenos GC, Koussidou T, Kapetis E. The treatment of pemphigus vulgaris. Experience with 48 patients seen over an 11-year period. Br J Dermatol 1995; 133: 83-7.

[7] Mutasim DF, Pelc NJ, Anhalt GJ (1993) Drug-induced pemphigus. Dermatol Clin 11: 463-471.

[8] Brenner S, Wolf R (1994) Possible nutritional factors in induced pemphigus. Dermatology 189: 337-339.

[9] Bystryn JC, Rudolph JL (2005) Pemphigus. Lancet 366: 61-73.

[10] Tron F, Gilbert D, Mouquet H, Joly P, Drouot L, Makni S, et al. (2005) Genetic factors in pemphigus. J Autoimmun 24: 319-328.

[11] Shamim T, Varghese VI, Shameena PM, Sudha S. Pemphigus vulgaris in oral cavity: Clinical analysis of 71 cases. Med Oral Patol Oral Cir Bucal. 2008;13:E622–6.

[12] Neville D, Allen B. Dermotological Disease. 2nd ed. Saunders; 2008. Oral and Maxillofacial Pathology; pp. 664–7.

[13] Ruocco E, Baroni A, Wolf R, Ruocco V (2005) Life-threatening bullous dermatoses: Pemphigus vulgaris. Clin Dermatol 23: 223-226.

[14] Dagistan S, Goregen M, Miloglu O, Cakur B (2008) Oral pemphigus vulgaris: a case report with review of the literature. J Oral Sci 50: 359-362.

[15] Black M, Mignogna MD, Scully C (2005) Number II. Pemphigus vulgaris. Oral Dis 11: 119-130.

[16] Ariyawardana A, Tilakaratne WM, Dissanayake M, Vitanaarachchi N, Basnayake LK, Sitheeque MA, et al. (2005) Oral pemphigus vulgaris in children and adolescents: a review of the literature and a case report. Int J Paediatr Dent 15: 287-293.

[17] Shamim T, Varghese VI, Shameena PM, Sudha S (2008) Pemphigus vulgaris in oral cavity: clinical analysis of 71 cases. Med Oral Patol Oral Cir Bucal 13: E622-E626.

[18] Tron F, Gilbert D, Mouquet H, Joly P, Drouot L, Makni S, et al. (2005) Genetic factors in pemphigus. J Autoimmun 24: 319-328.

[19] Scully C, Mignogna M (2008) Oral mucosal disease: pemphigus. Br J Oral Maxillofac Surg 46: 272-277.

[20] Camacho-Alonso F, López-Jornet P, Bermejo-Fenoll A (2005) A presentation of 14 cases and review of the literature. Med Oral Patol Oral Cir Bucal 10: 282-288.

[21] Ben Lagha N, Poulesquen V, Roujeau JC, Alantar A, Maman L (2005) Pemphigus vulgaris: a case-based update. J Can Dent Assoc 71: 667-672.

[22] Bystryn JC, Rudolph JL (2005) Pemphigus. Lancet 366: 61-73.

[23] Suárez-Fernández R, España-Alonso A, Herrero-González JE, Mascaró-Galy JM (2008) Manejo práctico de las enfermedades ampollosas autoinmunes más frecuentes. Actas Dermosifiliogr 99: 441-455.

[24] Prajapati V, Mydlarski PR (2008) Advances in pemphigus therapy. Skin Therapy Lett 13: 4-7.

[25] Murrell DF, Dick S, Ahmed AR, Amagai M, Barnadas MA, Borradori L (2008) Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. J Am Acad Dermatol 58: 1043-1046.

[26] Berookhim B, Fischer HD, Weinberg JM. Treatment of recalcitrant pemphigus vulgaris with the tumor necrosis factor alpha antagonist etanercept. Cutis 2004; 74: 245-7.

[27] Jacobi A, Shuler G, Hertl M. Rapid control of therapy-refractory pemphigus vulgaris by treatment with the tumour necrosis factor-alpha inhibitor infliximab. Br J Dermatol 2005; 153: 448-9.

[28] Shetty A, Marcum CB, Glass LF, Carter JD. Successful treatment of pemphigus vulgaris with etanercept in four patients. J Drugs Dermatol 2009; 8: 940-3.

[29] National Institute of Allergy and Infectious Diseases. Use of Infliximab for the Treatment of Pemphigus Vulgaris. In: ClinicalTrialsgov 2000.

[30] Garcia-Rabasco A, Alsina-Gibert M, Pau-Charles I, Iranzo P. Infliximab therapy failure in two patients with pemphigus vulgaris. J Am Acad Dermatol 2012; 67: e196-7.

[31] Ratnam KV, L PK, K TC. Pemphigus therapy with oral prednisolone regimens. A 5-year study. Int J Dermatol 1990; 29: 363-7.

[32] Murrell D, Amagai M, Barnadas M, et al. JAAD. Consensus statement on definitions of disease, endpoints, and therapeutic response for pemphigus. J Am Acad Dermatol 2008; 58: 1043-6.

[33] Harman K, Albert S, Black M. British Association of Dermatologists. Guidelines for the management of pemphigus. Br J Dermatol 2003; 149(926-37).

[34] Mentink L, Mackenzie M, Toth G, et al. Randomized controlled trial of adjuvant oral dexamethasone pulse therapy in pemphigus vulgaris: PEMPULS trial. Arch Dermatol 2006; 142: 570-6.